News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sunovion Pharmaceuticals Inc. and Afraxis, Inc. Announce Novel Drug Discovery Partnership



8/13/2013 10:07:38 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MARLBOROUGH, Mass. & SAN DIEGO--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) and Afraxis, Inc. today announced that they have signed a partnership agreement to utilize the unique Enhanced Spine Platform (ESP) developed by Afraxis, Inc. to accelerate Sunovion’s preclinical central nervous system (CNS) drug discovery process. The use of this proprietary platform will allow Sunovion to identify novel CNS compounds that are potentially superior to existing treatments. While the full financial terms have not been disclosed, Afraxis will be eligible for certain milestone payments for each compound through phase 2 clinical trial initiation.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES